Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotechnic who wrote (7643)	9/25/1997 2:06:00 PM
From: Henry Niman	of 32384

Biotechnic, I just reread a portion of the press release and I may have been focusing too much on diabetes and not thinking of other metabolic disease applications. The line in the press release that made me think that two diabetes deals were in the works was the comment by AGN's Lester Kaplan, "We are extremely optimistic about the potential of RXR compounds in type II diabetes and will be moving ALRT326 and ALRT4204 aggressively toward IND filing while we pursue corporate partnering opportunities for the compounds in the metabiolic disease area." An alternate interpretation of that statement is AGN is excited about LGND moving LGND's RXRs (Targretin, ALRT268, and ALRT324) into the type II diabetes area (AGN gets a generous royalty from LGND), and AGN is moving ALRT326 and ALRT4204 toward IND filing for something like cardiovascular or obesity markets (metabolic diseases). This would keep the number of diabetes programs at one and both areas could involve JNJ (via an AGN buyout and a LGND diabetes deal).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next